Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Institut Gustave Roussy

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

completed 13 May 2025

Decision date (initial)

2024-10-29

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

External identifiers

EU CT number

2024-515533-15-00

EudraCT number

2017-003622-33

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Safety, Efficacy

The primary objective of this randomized phase II trial is to evaluate the clinical benefits of the addition of atezolizumab to standard chemoradiotherapy (CRT) (first given concurrently with CRT, then continued as adjuvant treatment), compared with CRT alone, on investigator-assessed progression-free survival (PFS), as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

Secondary objectives 4

1. To evaluate the efficacy of atezolizumab plus standard CRT compared with CRT alone as measured by objective response rates, locoregional control and overall survival (OS).
2. To evaluate the safety of atezolizumab in combination with CRT compared to CRT alone, including the incidence and severity of acute and delayed radiation-induced side effects in the two treatment arms.
3. Translational research objectives of the study are: 1. To assess blood- and tissue-based biomarkers that are predictive of response to atezolizumab (i.e., predictive biomarkers), or are associated with outcomes independent of treatment (i.e., prognostic biomarkers). 2. To assess changes in blood- and tissue-based biomarkers during atezolizumab treatment.
4. Objective for ancillary study is : To determine the several biological changes during the treatment, by analysing the MRI sequences, in order to tailor the prescribed dose to improve therapy efficacy for further patients

Conditions and MedDRA coding

Locally advanced cervical cancer

Regulatory references

Plan to share IPD

Yes

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 12

1. Signed informed consent (after informing the patient).
2. Age ≥18 years old. Patients above 70 years old will be screened according to the G-8 screening tool. If required (G-8 score ≤14), a consultation with an onco-geriatrician will be held in order to confirm the patient eligibility.
3. Histologically confirmed cancer of the uterine cervix: squamous cell carcinoma (SCC), adenocarcinoma, or adenosquamous carcinoma
4. At least one evaluable lesion according to RECIST v1.1 criteria for the assessment of the principal judgment criteria. At baseline, lesion(s) must be ≥10 mm in the longest diameter (except lymp nodes which must have a short axis ≥15 mm).
5. International Federation of Gynecology and Obstetrics (FIGO 2009) classification (confirmed by clinical staging and/or imaging): (i) stage IB1-IIA tumour with positive pelvic nodal status, as assessed by magnetic resonance imaging (MRI) and/or fluorine-18 fluorodeoxyglucose positron emission tomography (18-FDG PET)/computerised tomography (CT); (ii) stage IIB-IVA tumour, regardless of pelvic lymph node involvement; (iii) stage IVB tumours only if the metastases are limited to the para-aortic lymph nodes. No evidence of metastatic disease outside the para-aortic area by primary staging (including clinical examination, pelvic MRI, 18-FDG PET, +/- laparoscopic para-aortic lymph node staging).
6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
7. Adequate haematologic and end-organ function, defined by the following laboratory results obtained within 15 calendar days prior to the first study treatment: a. Absolute neutrophil count (ANC) ≥1,500/mm3 (≥1.5 x 109/L) without granulocyte colony-stimulating factor (G-CSF) support. b. Total white blood cells (WBC) >2,000/mm3 (>2.0 x 109/L) (including Polymorphonuclear neutrophils > 1,500/mm3 or 1.5 x 109/L) c. Lymphocyte count ≥500/mm3 (≥ 0.5 x 109/L) d. Platelet count ≥ 100,000/mm3 (≥ 100 x 109/L) without transfusion. e. Haemoglobin ≥ 9.0 g/dL (90 g/L; patients may be transfused to meet this criterion). f. International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation. Patients receiving therapeutic anticoagulation should be on a stable dose. g. Creatinine <1.5 ULN or calculated creatinine clearance (CrCL) ≥ 45 mL/min (calculated using the Cockcroft-Gault formula). h. Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase <2.5 x ULN. i. Serum bilirubin <1.5 x ULN.
8. Proteinuria < 200 mg/dL (2 g/L). Patients with ureteral stent or with bladder invasion are eligible if the proteinuria is above the former threshold.
9. Ability to comply with the study protocol.
10. Geographical, social and psychological ability to undergo the follow-up required by the study.
11. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhoea) and not surgically sterile: a. Must agree to either use an acceptable contraceptive method* or to remain abstinent** (refrain from heterosexual intercourse) during the treatment period and for at least 5 months after the last dose of atezolizumab in arm B and at least 6 months after the last cisplatin/carboplatin dose in arm A. * Acceptable contraceptive methods include single or combined contraceptive methods that result in a failure rate of < 1% per year, such as: tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of < 1% per year. Barrier methods must always be supplemented with the use of a spermicide. ** Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. b. Must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.
12. Patients must be affiliated to a social security system or beneficiary of the same, as per local regulatory requirements

Exclusion criteria 27

1. Histological types of cervical cancer other than those listed in the inclusion criteria (based on FIGO 2009 classification), including: a. Stage IB1, IB2 and IIA cervical cancer with no regional lymph node metastases (N0). b. Stage IVB cervical cancer with presence of distant metastases other than para-aortic lymph node metastases.
2. Treatment with another investigational therapy within 30 days prior to initiation of the study drug.
3. Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the study other than for diagnosis. The following are not considered a major surgical procedure and are therefore permitted: (i) placement of central venous access catheter(s) (e.g., port or similar); (ii) surgical lymph node staging with no perioperative complications; (iii) placement of ureteral catheters.
4. History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins.
5. Known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the atezolizumab formulation.
6. Any contraindication to the use of cisplatin and/or carboplatin
7. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, meningoencephalitis, or glomerulonephritis (see Appendix 6 for a more comprehensive list of autoimmune diseases) with the following exceptions: patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone, patients with controlled Type 1 diabetes mellitus on a stable insulin regimen, and patients with mild autoimmune skin disorders (such as eczema or atopic dermatitis involving <10% of the skin) may be eligible for this study.
8. History of idiopathic pulmonary fibrosis (IPF, including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or active pneumonitis.
9. Peripheral neuropathy ≥grade 2.
10. Positive test for human immunodeficiency virus (HIV).
11. Active hepatitis B (positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C (positive hepatitis C virus antibody [HCVAb] test at screening). Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antibody [HBcAb] test) are eligible.
12. Prior surgery for cervical cancer unless cone resection and paraaortic lymphadenectomy.
13. Known active tuberculosis.
14. Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that such a live, attenuated vaccine will be required during the study. Note: Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 28 days prior to randomisation, during treatment or within 5 months following the last dose of atezolizumab.
15. Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or immune checkpoint targeting agents.
16. Prior pelvic radiotherapy, other radiotherapy, chemotherapy or immunotherapy.
17. Any malignancy other than the disease under study in the past 5 years excepting skin cancers such as BCC or SCC.
18. Pregnant or lactating women, or intending to become pregnant during the study.
19. For patient ≥ 70 years old with a G-8 score ≤ 14, unconfirmation of patient eligibility done by the onco-geriatrian at screening
20. History of clinically relevant cardiovascular disease, congestive heart failure (New York Heart Association [NYHA] Class II or greater; see Appendix 3), or a known left ventricular ejection fraction (LVEF) <50%, symptomatic coronary artery disease, poorly controlled cardiac arrhythmia, or myocardial infarction.
21. Active inflammatory bowel disease, lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome.
22. Serious infection requiring oral or IV antibiotics within 4 weeks prior to randomisation, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
23. Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomisation. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.
24. Treatment with systemic immunostimulatory agents (such as interferons or IL-2) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomisation.
25. Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator’s judgment.
26. Any other serious medical condition or abnormality in clinical laboratory tests that, in the investigator’s judgment, precludes the patient’s safe participation in and completion of the study.
27. Patients under judicial protection (curatorship, tutorship) and/or deprived of freedom.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. The primary endpoint is progression free survival (PFS), defined as the time from randomization to the first documented occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Data for patients without disease progression or death will be censored at the date of the last follow-up.

Secondary endpoints 5

1. Overall survival (OS), defined as the time from randomisation to death due to any cause.
2. Complete response rate at 8 weeks, defined as the percentage of patients with measurable disease at baseline, who have achieved complete response (CR) after treatment initiation, as determined by the investigator using RECIST v1.1 criteria.
3. Locoregional control, defined as the cumulative rate of locoregional recurrence or progression with censoring of deaths without locoregional recurrence or progression.
4. Distant tumour control: defined as the cumulative rate of (distant) metastatic events with censoring of deaths without metastatic progression. In case locoregional recurrence (or progression) and distant progression occur at the same time, the event will be counted as a distant event.
5. Toxicity, defined as any adverse drug reaction (AE assessed at least possibly related to any study treatment) that occurs within 6 months following brachytherapy (acute toxicity) or more than 6 months following brachytherapy (late toxicity). Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTC-AE v4.03) at each visit.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Gustave Roussy

Sponsor organisation

Institut Gustave Roussy

Address

114 Rue Edouard Vaillant

City

Villejuif

Postcode

94800

Country

France

Scientific contact point

Organisation

Institut Gustave Roussy

Contact name

Affaires réglementaires BPP

Public contact point

Organisation

Institut Gustave Roussy

Contact name

Affaires réglementaires BPP

Locations

1 EU/EEA country · 32 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 4 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications